Study aim: Evaluation of the SinaCurcumin efficacy as a supplement for treatment of mild to moderate COVID-19 Design: This is a non-randomized open label, parallel group clinical trial on 60 patients with mild to moderate covid-19 (30 patients in treatment group and 30 patients in control). Settings and conduct: This study will perform on 60 patients with clinical or laboratory diagnosis of mild to moderate covid-19 who refer to Sharif Clinic, Mashhad, Iran. They whether will received two sinacurcumin 40mg capsule twice daily for 2 weeks and then one capsule 40mg twice daily for 2weeks in treatment group or standard measures in control group. Participants/Inclusion and exclusion criteria: Inclusion criteria: Laboratory or radiologic or clinical diagnosis of mild to moderate COVID-19, age between 18-65y, sign of the written consent Exclusion criteria: more than 7d from the beginning of the symptoms, pregnancy or lactation, history of allergy to curcumin or turmeric, smoking (more than 5 cigarettes per day), adverse drug reaction occurrence, past medical diseases (e.g. kidney, hepatic, heart failure, complicated heart or brain disease, diabetes, chronic lung disease, malignancies, endocrine diseases, any immune system dysfunction, history of gallbladder, or active GI ulcer) Intervention groups: Treatment group: two capsule Sinacurcumin 40mg twice daily for 2 weeks, one capsule 40mg twice daily for two weeks Control group: no intervention Main outcome variables: Primary endpoints of the study are rates of treatment response and adverse drug reactions. Secondary endpoints are duration of hospitalization and patients' clinical outcomes.